Pelthos Therapeutics Inc. PTHS 深 滬
已收盤 02-06 16:00:00 美东时间
22.99
-0.331
-1.42%
華盛通- 最 高23.30
- 今 開22.25
- 成交量 6392股
- 最 低 22.25
- 昨 收 23.321
- 總市值 7096.28万
- 52周最高 54.29
- 市盈率 靜 --
- 換手率 0.21%
- 52周最低 9.00
- 委 比 0.00%
- 總股本 308.67万
- 歷史最高 60.00
- 量 比 0.85
- 振 幅 4.50%
- 歷史最低 4.50
- 每 手 1
- 風險率 7.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $60
Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $57 to $60.
01-26 21:55
Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance
Pelthos Therapeutics secured $30 million in financing from Horizon Technology Finance, with up to an additional $20 million for future growth. Funds will support the commercialization of its lead product ZELSUVMI™, recently acquired FDA-approved infectious disease products, and general corporate purposes. The facility is minimally dilutive to existing shareholders, with proceeds aimed at enhancing Pelthos' product portfolio and market reach.
01-13 13:30
On Dec 23, Pelthos Therapeutics Enters Asset Purchase Agreement With Hatchtech; Hatchtech Sells Rights To Xeglyze Product To Co. For $1.8M
On December 23, 2025, Pelthos Therapeutics Inc., a Nevada corporation (the "Company") entered into an Asset Purchase Agreement (the "Asset Purchase Agreement") with Hatchtech Pty Ltd ACN 098 559 409, an Australian
01-03 05:52
美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
2025-12-04 09:38
HC Wainwright & Co. Initiates Coverage On Pelthos Therapeutics with Buy Rating, Announces Price Target of $60
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Buy rating and announces Price Target of $60.
2025-12-03 20:06
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
2025-11-26 10:07
Roth Capital Initiates Coverage On Pelthos Therapeutics with Buy Rating, Announces Price Target of $57
Roth Capital analyst Jonathan Aschoff initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Buy rating and announces Price Target of $57.
2025-11-26 02:18
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
Oppenheimer Reiterates Outperform on Pelthos Therapeutics, Raises Price Target to $57
Oppenheimer analyst Jeff Jones reiterates Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $50 to $57.
2025-11-15 01:28
